- Home
- GDTC vs FGEN Comparison
GDTC vs FGEN Comparison
Compare GDTC & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- FGEN
- Stock Information
- Founded
- GDTC 2018
- FGEN 1993
- Country
- GDTC Singapore
- FGEN United States
- Employees
- GDTC N/A
- FGEN N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- FGEN Health Care
- Exchange
- GDTC Nasdaq
- FGEN Nasdaq
- Market Cap
- GDTC 28.0M
- FGEN 33.5M
- IPO Year
- GDTC 2023
- FGEN 2014
- Fundamental
- Price
- GDTC $2.35
- FGEN $0.30
- Analyst Decision
- GDTC Buy
- FGEN Strong Buy
- Analyst Count
- GDTC 1
- FGEN 1
- Target Price
- GDTC $5.00
- FGEN $10.00
- AVG Volume (30 Days)
- GDTC 9.6K
- FGEN 594.8K
- Earning Date
- GDTC 01-01-0001
- FGEN 05-12-2025
- Dividend Yield
- GDTC N/A
- FGEN N/A
- EPS Growth
- GDTC N/A
- FGEN N/A
- EPS
- GDTC N/A
- FGEN N/A
- Revenue
- GDTC $368,838.00
- FGEN $6,996,000.00
- Revenue This Year
- GDTC $5.37
- FGEN $232.81
- Revenue Next Year
- GDTC N/A
- FGEN $9.16
- P/E Ratio
- GDTC N/A
- FGEN N/A
- Revenue Growth
- GDTC N/A
- FGEN N/A
- 52 Week Low
- GDTC $1.20
- FGEN $0.18
- 52 Week High
- GDTC $4.05
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- GDTC 49.94
- FGEN 44.76
- Support Level
- GDTC $2.26
- FGEN $0.29
- Resistance Level
- GDTC $2.60
- FGEN $0.32
- Average True Range (ATR)
- GDTC 0.13
- FGEN 0.02
- MACD
- GDTC 0.00
- FGEN 0.00
- Stochastic Oscillator
- GDTC 40.38
- FGEN 26.25
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.